Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in ...

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology ...

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved ...

A Durham drugmaker has added another product to its portfolio with a recent acquisition.

Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from ...

Background.Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of ...

Xepi is a non-fluorinated quinolone antimicrobial cream approved by the FDA in 2017 for treating impetigo in patients two months and older. The treatment targets infections caused by Staphylococcus ...

A new strain of bacteria that can cause serious infections in children but evades standard treatments is spreading in Europe. MRSA (meticillin-resistant Staphylococcus aureus) is a type of bacteria ...

Most blisters (fluid-filled bubbles under the skin) heal on their own and aren’t cause for concern. But if your blister becomes infected, ignoring it can lead to potentially serious complications.

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMIXepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in anti ...